{
    "clinical_study": {
        "@rank": "122884", 
        "arm_group": {
            "arm_group_label": "BRCA2 Carriers", 
            "description": "All men identified to have a BRCA2 mutation as part of the Yale Cancer Genetic Counseling Program will be approached and offered participation in the study via our program newsletter, BRCA listserv, Facebook page and a targeted mailing"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the incidence of prostate cancer in men with the\n      BRCa2 gene mutation as an independent indicator for prostate cancer screening."
        }, 
        "brief_title": "Prostate Cancer Screening in Men With Germline BRCA2 Mutations", 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This is a cohort screening study to prospectively identify the incidence of prostate cancer\n      in a population of BRCA2 carriers.  All men identified to have a BRCA2 mutation as part of\n      the Yale Cancer Genetic Counseling Program will be approached and offered participation in\n      the study via our program newsletter, BRCA listserv, Facebook page and a targeted mailing.\n\n      Standard of care screening at the Yale Cancer Center for men with a normal prostate cancer\n      risk consists of a PSA test and prostate physical examination beginning at age 50 years and\n      if either is abnormal an MRI of the prostate followed by Fusion-targeted biopsy of the\n      prostate is performed."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  All men \u226530 years of age with at least a ten-year life expectancy\n\n          -  A known BRCA2 mutation\n\n          -  Ability to have an MRI\n\n          -  Able to give informed consent will be approached to participate in the study\n\n        Exclusion Criteria:\n\n          -  If a man has received or is currently receiving treatment for prostate cancer"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "30 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Study participants will be identified because of their BRCA2 mutation that places them at\n        increased risk for developing prostate cancer.  Because this is a pre-selected high-risk\n        population, and our goal is to establish the incidence of cancer and association of risk\n        factors with developing disease, all men \u226530 years of age, able to give informed consent,\n        and with at least a 5-10 year life expectancy will have PSA testing, prostate examination,\n        Pelvic MRI, and Artemis fusion prostate biopsy.\n\n        Men identified to have prostate cancer will be treated according to current standards of\n        care. Treatment for prostate cancer at the Yale Cancer Center is largely based on clinical\n        risk; options include, but are not limited to, active surveillance for appropriate men\n        with low risk disease, treatment with curative intent for men with localized intermediate\n        and high risk prostate cancer, and systemic therapy for men with metastatic disease."
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 30, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02154672", 
            "org_study_id": "1402013376"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 30, 2014", 
        "location": {
            "contact": {
                "email": "Preston.Sprenkle@yale.edu", 
                "last_name": "Preston Sprenkle, MD", 
                "phone": "203-785-2052"
            }, 
            "facility": {
                "address": {
                    "city": "New Haven", 
                    "country": "United States", 
                    "state": "Connecticut"
                }, 
                "name": "Yale University"
            }, 
            "investigator": {
                "last_name": "Preston Sprenkle, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Prostate Cancer Screening in Men With Germline BRCA2 Mutations", 
        "overall_official": {
            "affiliation": "Yale University", 
            "last_name": "Preston Sprenkle, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Incidence of Prostate Cancer in BRCA2 Mutation Carriers", 
            "safety_issue": "No", 
            "time_frame": "Up to 3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02154672"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Yale University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yale University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}